Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide
Crossref DOI link: https://doi.org/10.1007/s00277-014-2238-2
Published Online: 2014-10-28
Published Print: 2015-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Lau, I-Jun
Smith, Dean
Aitchison, Robin
Blesing, Norbert
Roberts, Pamela
Peniket, Andrew
Yong, Kwee
Rabin, Neil
Ramasamy, Karthik
Text and Data Mining valid from 2014-10-28